pfizer: search

Pfizer decision "> Appeal court clarifies patent issues in Pfizer decision

On 9th May 2008 the Barcelona Court of Appeal issued a decision dealing with a number of key issues in the field of patents. Pfizer had sued Bayvit (now known as Stada) for infringement of its patents for amlodipine (ES 520,389 and EP 255,944), and Bayvit filed a counterclaim on the basis of nullity of the patents invoked.

Matrix challenges Pfizer's antifungal drug patent

Singapore, Oct 30, 2008: Mylan’s Indian subsidiary, Matrix Laboratories has challenged Pfizer’s patents for its ‘Vfend’ tablets with the filing of its Abbreviated New Drug Application (ANDA). As Pfizer did not file a lawsuit against Matrix within the 45-day time period provided, Matrix's ANDA will be eligible for final approval as soon as regulatory review is complete.

Pfizer US job cuts help Indian techies

MUMBAI: Pharma giant Pfizer US is believed to be laying off local IT workers from their unit in Connecticut and replacing them with Indian staff sent on H1B visas.

Pfizer Starts Stem Cell R&D Unit

GT Solar Sees Brighter IPO Skies; Pfizer, Merck, and Eli Lilly Back Boston Startup; GSI Group Beams out $360M for Excel Technology & More Deals News

Pfizer sues over snack

An Austrian pumpkin seed oil producer faces possible legal action by pharmaceutical giant Pfizer, the producer of Viagra, over his "Styriagra" chocolate-coated pumpkin seeds, according to media reports.

Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods

Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods

Pfizer gets in on stem cell research

fizer (New York) is stepping into the stem cell business, according to a Wall Street Journal health blog. The blog quoted a Reuters report that said the company opened a “regenerative medicine unit” in Cambridge, Mass. last spring, and plans to open another similar shop in Cambridge, U.K., in November. According to the blog, the U.S. shop will focus on heart disease and diabetes; the U.K. operation will focus on ophthalmology and the central nervous system.

Sweet pumpkin seed snack leaves businessman with sour taste

VIENNA (AFP) - An Austrian pumpkin seed oil producer faces possible legal action by pharmaceutical giant Pfizer, the producer of Viagra, over his "Styriagra" chocolate-coated pumpkin seeds, according to media reports.

A new president, a look at the future, but the world goes on

Yes, Barack Hussein Obama will be the 44th president of the United States, once he is sworn into office in January. Now that the election is over and Mr. Obama is already starting to pick staff members, we can all go back to our daily lives. Other things did happen this week: The Supreme Court heard the first oral arguments in the Wyeth vs. Levine preemption case; GlaxoSmithKline is cutting 1,000 people from its salesforce and is consolidating its U.S. headquarters; Sanofi-Aventis and Pfizer have ended research on their obesity drugs; and drug companies apparently hid millions of dollars in payments to physicians in Vermont and Minnesota by designating them as “trade secrets.” There’s all sorts of other news out there as well, so I’ll get to it.

Gene Network Sciences Creates Quant Finance Spin-Off

CAMBRIDGE, Mass., Nov. 25 -- Gene Network Sciences, Inc. (GNS) today announced that it has created a subsidiary company, Fina Technologies, Inc. (Fina) to leverage its proprietary Reverse Engineering, Forward Simulation (REFS) software platform in a new arena -- that of quantitative financial trading and e-commerce. REFS was originally developed to rapidly process raw clinical and genomics data to identify drug targets, biomarkers and drug and disease mechanisms for disease categories such as cancer, diabetes and inflammation, and has been used by GNS in partnership with leading pharmaceutical companies and clinical research organizations such as Johnson & Johnson, Pfizer, Novartis AG, Biogen Idec, UCSF Cancer Center, and Jackson Laboratories for these purposes.

Search took 0.02 seconds.